author |
|
created | [InstanceEdit:9750151] Orlic-Milacic, Marija, 2021-08-10 |
dbId | 9750163 |
displayName | https://cancerres.aacrjournals.org/content/78/13_Supplement/4791 |
schemaClass | URL |
title | Abstract 4791: OMO-1, a potent, highly selective, orally bioavailable, MET kinase inhibitor with a favorable preclinical toxicity profile, shows both monotherapy activity, against MET pathway-driven tumors, and EGFR TKI combination activity in acquired resistance models |
uniformResourceLocator | https://cancerres.aacrjournals.org/content/78/13_Supplement/4791 |
© 2024 Reactome